CYP19A1 and breast cancer: More specifically, LMTK3 inhibitors could be combined alongside aromatase inhibitors (AIs) as an alternative to treatment with CDK4/6 inhibitors to improve patient outcome in estrogen receptor positive (ER+) BC [37,38].